Role of Psychosomatic Symptoms in COVID-19 Vaccine Hesitancy

Desai, Saral; Kainth, Tejasvi; Yadav, Garima; Kochhar, Hansini; Srinivas, Sushma; Kamil, Saher Hoda; Du, Wei

doi:10.3390/vaccines11050922

Cited by 3 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 Nonetheless, this might be associated with vaccination behavior and psychological distress to the rapid approval of COVID-19 vaccinations during the pandemic that raised concerns and vaccination hesitancy rather than the vaccine itself. 25 Therefore, it is important to explore and manage public acceptance of vaccination.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Dyu,

Leung,

Simões-e-Silva

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

ChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database in Brazil. Individuals diagnosed with COVID-19 and schizophrenia were included in the study. The exposures were 0, 1, and 2 doses of ChAdOx1-S. The outcome of mortality was measured in hazard ratios (HR), calculated using multivariable Cox regression models. The study included 1,929 positive cases of COVID-19 in schizophrenia patients. After adjusting for age, socioeconomic factors, and comorbidities, we observed a significant 55% decrease in the hazard of mortality in the 2-dose vaccination group (HR 0.45, 95% CI: 0.310–0.652) compared to the unvaccinated. Surprisingly, our results did not show any significant reduction in the hazard of mortality in the 1 dose vaccination group (HR 1.278, 95% CI: 0.910–1.795). The effectiveness of two doses of ChAdOx1-S in individuals with schizophrenia aligns with findings from studies on the general population. That one dose was insignificant. Overall, these findings are important for informing public health decisions – prioritizing individuals with schizophrenia for vaccinations and managing acceptance of vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Dyu,

Leung,

Simões-e-Silva

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…While not a novel issue, vaccine hesitancy has gained unprecedented visibility due to the dissemination of anti-vaccination misinformation on social media platforms, further exacerbated by the ongoing SARS-CoV-2 pandemic [ 5 ]. The pandemic’s context has witnessed the rapid emergency authorization and approval of numerous COVID-19 vaccines, raising concerns about their safety, potential adverse effects, and long-term impacts due to the lack of longitudinal data [ 8 , 9 ]. Consequently, apprehension and hesitancy toward these vaccines have arisen, prompting the need for healthcare systems to address vaccine hesitancy through evidence-based interventions and to devise COVID-19 vaccine strategies that effectively tackle emerging mutations of the virus [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing the Healthcare Workers’ Willingness to Receive the COVID-19 Booster Dose in Tuscany (Italy)

Guarducci,

Mereu,

Golinelli

et al. 2023

Vaccines

View full text Add to dashboard Cite

Background: The World Health Organization has defined vaccine hesitancy as behavior influenced by several factors, including trust in the vaccine itself or its provider or the perceived need for vaccination. The aim of this study was to investigate the factors influencing the willingness to receive the COVID-19 vaccine among the employees and healthcare professionals of the Central Tuscany Local Health Authority (CT-LHA) in Italy. Methods: From July to October 2022, a cross-sectional study was conducted. An online questionnaire was administered to 7000 employees of the CT-LHA. The questionnaire analyzed the factors that influenced receiving the booster dose of the COVID-19 vaccine. The sample was stratified by gender, age, type of occupation (healthcare or non-healthcare workers), and seniority. Incomplete questionnaires were excluded. A chi-squared test was performed through STATA. The significance level was set at 95%. Results: Of the questionnaires administered, 1885 (26.9%) questionnaires were eligible for the study. In the previous vaccination campaign, the healthcare workers (HCWs) considered the vaccine used by CT-LHA as safe, in contrast to non-healthcare workers (N-HCWs), who considered it less secure (p < 0.05). The HCWs showed a higher propensity for vaccine safety to receive the booster dose than N-HCWs. N-HCWs appeared to be less affected by an updated booster dose than HCWs (p < 0.05). Conclusions: The factors studied appear to influence HCWs differently from N-HCWs. Both HCWs and N-HCWs would choose an upgraded mRNA vaccine for the booster dose.

show abstract

Psychological Factors Shaping Vaccine Hesitancy During COVID-19 in India

Lakhotia,

Chakraborty,

Thirani

et al. 2024

Advances in Finance, Accounting, and Economics

View full text Add to dashboard Cite

Vaccine hesitancy represents the refusal or delay in vaccine acceptance, despite its availability. In developing countries, such as India, villages and areas with diminished awareness served as a breeding ground for rumors and false beliefs regarding COVID-19 vaccines. In this context, this study aimed to understand the behavioural, emotional, and cognitive factors contributing to the spread of misinformation and rumours. By employing semi-structured interview, this qualitative study collected data from participants. Thematic analysis revealed that negative perception towards vaccine, belief in non-scientific healing practices, negative nocebo emotional reactions led to vaccine hesitancy. These findings have implication in designing choice architecture and nudging desirable behaviour for intervention plan to curb future resistance and develop effective communication strategies to avert similar outbreaks.

show abstract

Role of Psychosomatic Symptoms in COVID-19 Vaccine Hesitancy

Cited by 3 publications

References 58 publications

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Factors Influencing the Healthcare Workers’ Willingness to Receive the COVID-19 Booster Dose in Tuscany (Italy)

Psychological Factors Shaping Vaccine Hesitancy During COVID-19 in India

Contact Info

Product

Resources

About